OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28’s development path directly into a pivotal Phase 3 study.
With the vast majority of PMD patients having no FDA-approved therapeutic option, OMT-28 addresses…